Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

MNOV
Medicinova, Inc.
stock NASDAQ

Market Open
Aug 20, 2026 11:53:29 AM EDT
1.36USD-1.812%(-0.02)20,489
1.12Bid   1.53Ask   0.41Spread
Pre-market
Aug 19, 2026 9:01:30 AM EDT
1.38USD-0.362%(-0.01)0
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
06:31AM EST  MediciNova Receives A Notice Of Allowance For A New Patent Covering MN-001 And MN-002 For Hepatic Ballooning In Canada   Benzinga
06:30AM EST  MediciNova Receives a Notice of Allowance for a New Patent   GlobeNewswire Inc
Jan 27, 2022
06:30AM EST  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from theEuropean Patent Officefor a pending patent applicationwhich covers MN-166 (ibudilast) for the treatment of alcohol use disorder.   GlobeNewswire Inc
Jan 26, 2022
08:29AM EST  The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data   Benzinga
06:34AM EST  MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe   Benzinga
06:30AM EST  MediciNova Receives a Notice of Intention to Grant for a New   GlobeNewswire Inc
Dec 13, 2021
06:34AM EST  MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For The Treatment Of ALS   Benzinga
06:30AM EST  MediciNova Receives Notice of Allowance forNew Patent   GlobeNewswire Inc
Dec 10, 2021
06:33AM EST  MediciNova Reports MN-166 Poster Presentation For Int'l. Symposium On Amyotrophic Lateral Sclerosis/Motor Neurone Disease Dec. 7-10   Benzinga
06:30AM EST  MediciNova Announces MN-166 (ibudilast) Poster Presentation at the   GlobeNewswire Inc
Nov 23, 2021
09:43AM EST  Zacks Small-Cap Research Sets $27 Valuation On MediciNova   Benzinga
Nov 22, 2021
06:32AM EST  MediciNova Announces New Data Regarding MN-166 In Glioblastoma Presented At The 26th Annual Meeting Of The Society For Neuro-Oncology   Benzinga
06:30AM EST  MediciNova Announces New Data regarding MN-166 (ibudilast) in   GlobeNewswire Inc
Nov 11, 2021
06:01PM EST  MediciNova Announces MN-001 Data Regarding Lipid Metabolism In NASH/NAFLD To Be Presented At The Liver Meeting 2021   Benzinga
06:00PM EST  MediciNova Announces MN-001 (tipelukast) Data regarding Lipid   GlobeNewswire Inc
Nov 10, 2021
06:48PM EST  MediciNova Highlights New Data Related To MN-166 In Uveal Melanoma Presented At CURE Global Science Meeting   Benzinga
Oct 21, 2021
12:11PM EDT  MediciNova Announces Abstract Regarding The Mechanism By Which MN-001 Alters Triglyceride Metabolism Accepted For Presentation At The 19th International Symposium On Atherosclerosis   Benzinga
06:30AM EDT  MediciNova Announces Abstract regarding the Mechanism by which   GlobeNewswire Inc
Sep 2, 2021
11:00PM EDT  MediciNova to Participate in the Morgan Stanley 19th Annual Global   GlobeNewswire Inc
Sep 1, 2021
06:30AM EDT  MediciNova Announces MN-001 Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting 2021   Benzinga
06:30AM EDT  MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid   GlobeNewswire Inc
Aug 30, 2021
06:31AM EDT  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND   Benzinga
06:30AM EDT  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for   GlobeNewswire Inc
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
10:14AM EDT  MediciNova Granted U.S. Patent Titled 'Treatment of progressive neurodegenerative disease with ibudilast'   Benzinga
Aug 2, 2021
04:52PM EDT  MediciNova Announces Effective July 31, 2021, Edward Stepanow Resigned As Chief Financial Officer; Douglas Paulin To Serve CFO   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 6, 2021
06:33AM EDT  MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For The Treatment Of Ophthalmic Disease   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from theU.S.Patent andTrademark Officefor a pending patent application which covers MN-166 (ibudilast) for the treatment of ophthalmic disease.   GlobeNewswire Inc
Jun 29, 2021
06:30AM EDT  MediciNova to Present at the Ladenburg Thalmann 2021 Virtual   GlobeNewswire Inc
Jun 28, 2021
08:37AM EDT  MediciNova To Test Ibudilast In BARDA's Validated Mouse Model Of Chlorine-Induced Pulmonary Injury   Benzinga
06:31AM EDT  MediciNova To Conduct Mouse Study Under Partnership With BARDA To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-induced Lung Injury   Benzinga
06:30AM EDT  MediciNova to Conduct Mouse Study under Partnership with BARDA to   GlobeNewswire Inc
Jun 27, 2021
06:31AM EDT  MNOV: Positive Results for MN-166 in Phase 2 AUD   Benzinga
Jun 22, 2021
02:43PM EDT  MediciNov Sees Volume After Zacks Research Raises Price Target To $28   Benzinga
Jun 21, 2021
10:56AM EDT  MediciNova, Inc. (MNOV) shares are trading above 17 percent on Monday morning after the company announced positive results from phase 2 trial of MN-166 or ibudilast in alcohol use disorder or AUD.   RTTNews
06:53AM EDT  Biopharmaceutical company MediciNova, Inc. (MNOV) announced Monday positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD).   RTTNews
06:36AM EDT  MediciNova Announces Positive Results From Phase 2 Trial Of MN-166 In Alcohol Use Disorder   RTTNews
06:30AM EDT  MediciNova Announces Positive Results from Phase 2 Trial of MN-166 in Alcohol Use Disorder Published in Nature's Translational Psychiatry Journal   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Natures Translational Psychiatry.   GlobeNewswire Inc
Jun 18, 2021
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jun 14, 2021
06:30AM EDT  MediciNova to Participate in Maxim Group LLC Fireside Chat   GlobeNewswire Inc
Jun 7, 2021
06:31AM EDT  MediciNova Initiates Sheep Study Under Partnership With BARDA To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-Induced Lung Injury   Benzinga
06:30AM EDT  MediciNova Initiates Sheep Study under Partnership with BARDA to   GlobeNewswire Inc
Jun 2, 2021
06:41AM EDT  MNOV: Phase 3 ALS Trial Ongoing   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
05:41PM EDT  MediciNova Q2 EPS $0.00, Up From $(0.06) YoY   Benzinga
04:30PM EDT  - Completed $20M private placement financing with 3D Investment Partners -   GlobeNewswire Inc
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
Apr 22, 2021
06:30AM EDT  MediciNova Receives Gene Therapy Milestone Payments of $4M   Benzinga
06:30AM EDT  MediciNova Receives Gene Therapy Milestone Payments   GlobeNewswire Inc
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
06:30AM EDT  MediciNova to Participate in the B. Riley Neuroscience Conference   GlobeNewswire Inc
Apr 15, 2021
06:30AM EDT  MediciNova to Participate in the UBS Global Healthcare Virtual   GlobeNewswire Inc
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Mar 15, 2021
09:52AM EDT  MediciNova Shares Spiking Higher; Hearing Unknown Research Firm Sets $23 Price Target   Benzinga
Mar 10, 2021
02:37PM EST  Mid-Afternoon Market Update: Dow Surges 500 Points; US Budget Deficit Widens In February   Benzinga
12:53PM EST  Mid-Day Market Update: Dow Jumps Over 400 Points; Just Energy Shares Slide   Benzinga
10:12AM EST  Mid-Morning Market Update: Markets Open Higher; Campbell Soup Reports In-Line Earnings   Benzinga
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2021   Benzinga
09:59AM EST  Shares of MediciNova Inc (MNOV) are surging over 67% Wednesday morning, following the biopharmaceutical company's announcement on a partnership with BARDA to develop chlorine gas-induced lung injury treatment.   RTTNews
09:32AM EST  Maxim Group Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $15   Benzinga
07:26AM EST  The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link   Benzinga
Mar 9, 2021
05:42PM EST  Shares of MediciNova Inc. (MNOV) surged over 100% in extended trading session on Tuesday after the biopharmaceutical company announced a partnership with BARDA to develop MN-166 as a medical countermeasure against chlorine gas-induced lung injury.   RTTNews
04:00PM EST  MediciNova Reports Partnership With Biomedical Advanced Research and Development Authority (BARDA) To Develop MN-166 As Medical Countermeasure Against Chlorine Gas-Induced Lung Injury   Benzinga
04:00PM EST  MediciNova Announces Partnership with BARDA to Develop MN-166   GlobeNewswire Inc
Mar 8, 2021
06:50AM EST  MediciNova to Participate in M Vest LLC and Maxim Group LLC   GlobeNewswire Inc
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
06:31AM EST  MediciNova To Discontinue Development Of A SARS-CoV-2 Vaccine   Benzinga
06:30AM EST  MediciNova Announces Update on   GlobeNewswire Inc
Jan 31, 2021
06:00PM EST  MediciNova Announces Closing of US$20 Million Private Placement   GlobeNewswire Inc
Jan 21, 2021
04:23PM EST  MediciNova 13D From 3D Investment Partners Shows 11.3% Stake In Co.   Benzinga
Jan 18, 2021
06:03PM EST  MediciNova Received Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of ALS in Japan   Benzinga
06:00PM EST  MediciNova Receives Notice of Allowance forNew Patent   GlobeNewswire Inc
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 11, 2021
09:30PM EST  MediciNova Enters into US$20 Million Securities Purchase Agreement   GlobeNewswire Inc
Dec 29, 2020
06:44AM EST  MediciNova Inc. (MNOV) said Tuesday that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis.   RTTNews
06:32AM EST  MediciNova Receives Notice Of Allowance For New Patent Covering MN-166   RTTNews
06:31AM EST  MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For Treatment Of Progressive MS   Benzinga
06:30AM EST  MediciNova Receives Notice of Allowance forNew Patent   GlobeNewswire Inc
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
06:30AM EST  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 21, 2020.   GlobeNewswire Inc
Nov 25, 2020
06:33AM EST  MediciNova Announces Positive Optical Coherence Tomography Results From SPRINT-MS Phase 2b Trial Of MN-166   RTTNews
06:32AM EST  MediciNova Highlights Publication Of SPRINT-MS Phase 2b Trial Of MN-166 Trial In Multiple Sclerosis Journal   Benzinga
06:30AM EST  MediciNova Announces Positive Optical Coherence Tomography Results   GlobeNewswire Inc
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
06:33AM EST  MediciNova Announces Initiation Of Master Virus Seed Stock Production For Its Intranasal COVID-19 Vaccine Using BC-PIV Vector Technology   Benzinga
06:30AM EST  MediciNova Announces Initiation of Master Virus Seed Stock   GlobeNewswire Inc
Nov 13, 2020
05:35AM EST  MediciNova Announced Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience 2020   Benzinga
Oct 22, 2020
06:38AM EDT  MediciNova, In Collaboration With University Of Sydney And The Australasian Gastro-Intestinal Trials Group, Announces Plans For A Multi-center, Phase 2b Study To Evaluate MN-166 (ibudilast) In Chemotherapy-Induced Peripheral Neuropathy   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a multi-center, placebo-controlled, randomized Phase 2b trial to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy (CIPN).   GlobeNewswire Inc
Oct 21, 2020
06:34AM EDT  MediciNova Appoints Carolyn Beaver To Its Board   RTTNews
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Ms. Carolyn Beaver to its Board of Directors and as Chair of its Audit Committee.   GlobeNewswire Inc
Oct 13, 2020
06:32AM EDT  MediciNova To Present Findings On MN-001 In Acute Liver Injury Model At The Liver Meeting Digital Experience 2020 Nov. 13-16   Benzinga
06:30AM EDT  MediciNova Announces Positive Findings on MN-001 (tipelukast) in   GlobeNewswire Inc
Sep 24, 2020
02:31PM EDT  Mid-Afternoon Market Update: Dow Surges 250 Points; Owens & Minor Shares Spike Higher   Benzinga
02:05PM EDT  Mid-Day Market Update: US Stocks Turn Higher; Kubient Shares Plunge   Benzinga
06:34AM EDT  MediciNova: Positive Clinical Findings Published In Cancer Chemotherapy And Pharmacology On MN-166   RTTNews
06:32AM EDT  MediciNova Announces Positive Clinical Results Regarding MN-166 for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive clinical findings published in Cancer Chemotherapy and Pharmacology regarding MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy (CIPN).   GlobeNewswire Inc
Sep 23, 2020
11:29AM EDT  Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates   Benzinga
10:29AM EDT  MediciNova, Inc. (MNOV) shares are rising on Wednesday morning trade after the biopharma company announced the intranasal SARS CoV-2 vaccine prototype for COVID-19.   RTTNews
10:11AM EDT  Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates   Benzinga
09:27AM EDT  MediciNova Inc.'s (MNOV) intranasal BC-PIV SARS-CoV-2 vaccine has successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen (Ag) of SARS-CoV-2 in mice.   RTTNews
06:46AM EDT  MediciNova Says Intranasal BC-PIV SARS-CoV-2 Vaccine Induced Systemic IgG & Mucosal IgA Neutralizing Antibodies In Mice   RTTNews
06:45AM EDT  MediciNova: Intranasal BC-PIV SARS-CoV-2 Vaccine Induced Systemic IgG And Mucosal IgA Neutralizing Antibodies In Mice   RTTNews
06:32AM EDT  MediciNova Announces Its Intranasal COVID-19 Vaccine 'Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology'   Benzinga
06:30AM EDT  MediciNova Announces that its Intranasal COVID-19 Vaccine   GlobeNewswire Inc
Sep 11, 2020
06:39AM EDT  BioComo: Intranasal RS Virus Vaccine Induced Neutralizing Antibodies Against RS Virus In Mice Using BC-PIV Technology   RTTNews
06:32AM EDT  MediciNova Reports Co Developer Of Co.'s Coronavirus Vaccine, BioComo, Announced Its Respiratory Syncytial Virus Vaccine Using BC-PIV Technology Induced High Neutralizing Antibodies In Mice   Benzinga
06:30AM EDT  MediciNova Announces that BioComos Intranasal RS   GlobeNewswire Inc
Sep 1, 2020
06:32AM EDT  MediciNova Says 'we have confirmed that the SARS-CoV-2 specific protein antigen mounted on their membrane surfaces binds with ACE2, which is a known receptor of SARS-CoV-2.'   Benzinga
06:32AM EDT  MediciNova Announces 'Development Progress' On Intranasal Formulation Of SARS-CoV-2 Vaccine For COVID-19   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a viral vector platform technology developed by Mie University and BioComo.   GlobeNewswire Inc
Aug 6, 2020
01:24PM EDT  MediciNova shares are trading higher after the company announced the results from its phase 2 trial of MN-166 in alcohol disorder demonstrated that ibudilast significantly reduced basal, daily alcohol craving in AUD patients.   Benzinga
07:33AM EDT  MediciNova Announces Presentation Of Positive Results From Phase 2 Trial Of MN-166 In Alcohol Use Disorder At The American Psychological Association 2020 Annual Convention   Benzinga
06:30AM EDT  MediciNova Announces the Presentation of Positive Results from   GlobeNewswire Inc
Aug 4, 2020
06:30AM EDT  MediciNova to Participate in the Morgan Stanley Virtual 18th   GlobeNewswire Inc
Jul 28, 2020
12:05PM EDT  Mid-Day Market Update: Crude Oil Down Over 1%; Eastman Kodak Shares Jump   Benzinga
10:15AM EDT  Mid-Morning Market Update: Markets Open Lower; McDonald's Profit Misses Views   Benzinga
09:47AM EDT  Morning Market Stats in 5 Minutes   Benzinga
Jul 27, 2020
02:54PM EDT  Mid-Afternoon Market Update: Nasdaq Surges 140 Points; MediciNova Shares Spike Higher   Benzinga
12:07PM EDT  Mid-Day Market Update: Gold Jumps 2%; WiMi Hologram Cloud Shares Plummet   Benzinga
10:25AM EDT  Shares of MediciNova, Inc. (MNOV) are currently gaining nearly 25% after the company said it is developing vaccine for coronavirus in collaboration with BioComo and Mie University Japan.   RTTNews
07:35AM EDT  MediciNova, Inc. (MNOV) has reached a deal with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine.   RTTNews
06:53AM EDT  MediciNova Enters Agreement With BioComo, Mie University For Joint Development Of SARS-CoV-2 Vaccine   RTTNews
06:34AM EDT  MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan   Benzinga
06:30AM EDT  MediciNova Announces SARS-CoV-2 Vaccine Joint Development with   GlobeNewswire Inc
Jul 20, 2020
06:30AM EDT  MediciNova to Participate in Panel Discussion at the B. Riley FBR   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC